European Union - English - EMA (European Medicines Agency)

akcea therapeutics ireland limited - volanesorsen sodium - hyperlipoproteinemia type i - other lipid modifying agents - waylivra is indicated as an adjunct to diet in adult patients with genetically confirmed familial chylomicronemia syndrome (fcs) and at high risk for pancreatitis, in whom response to diet and triglyceride lowering therapy has been inadequate.,